MIAMI, Jan. 13, 2022 /PRNewswire/ — ArisGlobal, the leading provider of life sciences software that automates core drug development processes with its end-to-end technology platform LifeSphere®, today announced its third consecutive year of record growth, driven by double digit revenue growth, talent acquisitions, and strong industry adoption of the LifeSphere platform.
A thirty-year veteran of the life sciences R&D software industry that counts 30 of the top 50 global biopharma companies and six global health authorities – including the US FDA – among its customer base, ArisGlobal’s growth is fueled by a trend toward digital transformation within life sciences companies. Born in the cloud, LifeSphere is an intuitive, intelligent, and unified platform that helps biopharmas of all sizes bring safer products to market more quickly. ArisGlobal’s record growth in 2021 is highlighted by:
Since announcing further investment by Nordic Capital, ArisGlobal has accelerated product enhancements across the LifeSphere platform while onboarding substantial industry talent, with approximately 600 new hires in 2021 alone.
“ArisGlobal’s sustained growth is a true testament to the level of innovation and quality we’ve pioneered since day one. We’re humbled that leading life sciences organizations continue to adopt our LifeSphere platform across domains, with many new customers joining the ArisGlobal community in 2021. In 2022, we are focused on delivering even more value to our customers through new product offerings and investments across key areas of the company,” said Sankesh Abbhi, President and CEO, ArisGlobal.
Looking toward 2022, ArisGlobal will continue to invest heavily into its LifeSphere platform, fueling advancements to its market-leading capabilities in Drug Safety and Medical Affairs, where the Company has been recognized for being first in the industry to deliver cloud applications powered by cognitive computing. The company is also prioritizing innovation and automation within its Clinical Development and Regulatory Affairs portfolios, with significant investments being made across talent, technology, and customer experience.
ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.
Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.
View original content to download multimedia:https://www.prnewswire.com/news-releases/arisglobal-closes-2021-with-tremendous-growth-across-customer-base-talent-and-revenue-further-solidifying-its-leadership-in-life-sciences-rd-software-301459750.html
SOURCE ArisGlobal
Toronto, Ontario--(Newsfile Corp. - July 9, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…
NEW YORK, July 9, 2024 /PRNewswire/ -- Scanning electrochemical microscopy (SECM) is used for imaging…
SAN DIEGO, July 9, 2024 /PRNewswire/ -- Puro Sound Labs, a leader in safe listening technology,…
NEW YORK, July 9, 2024 /PRNewswire/ -- Real-time Location Systems (RTLS) are technologies used to…
Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities SAN DIEGO, July 9, 2024 /PRNewswire/ --…
U.S. health systems are increasingly embracing ambient documentation solutions to reduce providers' administrative workloads and…